- Home
- GVA vs CRNX Comparison
GVA vs CRNX Comparison
Compare GVA & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GVA | CRNX |
|---|---|---|
| Founded | 1922 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.1B |
| IPO Year | 1990 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GVA | CRNX |
|---|---|---|
| Price | $116.14 | $49.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $105.00 | $71.00 |
| AVG Volume (30 Days) | 634.1K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | ★ 68.53 | N/A |
| EPS | ★ 3.67 | N/A |
| Revenue | ★ $4,236,312,000.00 | $1,535,000.00 |
| Revenue This Year | $11.29 | $425.31 |
| Revenue Next Year | $10.61 | $943.50 |
| P/E Ratio | $31.38 | ★ N/A |
| Revenue Growth | 6.87 | ★ 47.74 |
| 52 Week Low | $69.08 | $24.10 |
| 52 Week High | $115.88 | $60.25 |
Technical Indicators
Market Signals| Indicator | GVA | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 79.75 | 65.11 |
| Support Level | $107.77 | $46.49 |
| Resistance Level | $110.31 | $50.98 |
| Average True Range (ATR) | 2.43 | 1.95 |
| MACD | 1.04 | 0.35 |
| Stochastic Oscillator | 89.23 | 78.51 |
Price Performance
Historical ComparisonAbout GVA Granite Construction Incorporated
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.